ArticleNPP - digital psychiatry and neuroscience2026
Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper.
Article in NPP - digital psychiatry and neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric drug development remains constrained by diagnostic heterogeneity, insufficient and inconsistent drug response, high placebo response rates, and the absence of validated biomarkers that can reliably guide patient stratification, trial design, and regulatory decision-making. Despite substantial advances in neuroscience, few biomarkers in psychiatry have progressed beyond exploratory use, limiting the translation of mechanistic insights into effective therapeutics. The process of implementing biomarkers in psychiatry requires new levels of organization and coordination across many stakeholders, each with their own priorities. To date, however, no comprehensive roadmap exists to align scientific, regulatory, clinical, and commercial stakeholders around the development and implementation of predictive biomarkers in psychiatry. This position paper, developed by the American College of Neuropsychopharmacology (ACNP) Precompetitive Stakeholder Task Force and informed by work from the European College of Neuropsychopharmacology (ECNP) on the Precision Psychiatry Roadmap, brings together key stakeholders to begin the process of engaging in coordinated efforts. By integrating scientific, regulatory, and commercial perspectives, we clarify biomarker definitions and contexts of use, review current FDA regulatory pathways and gaps, and synthesize lessons from real-world examples. We highlight emerging biomarker modalities including fluid-based, digital, electrophysiological, neuroimaging, and multimodal approaches, and propose strategies to de-risk their adoption through standardized platforms, early regulatory engagement, and scalable trial designs. Emphasis is placed on precompetitive collaboration, large-scale data harmonization, and stakeholder alignment to accelerate reproducibility, regulatory interpretability, clinical utility, and improved use of experimental systems. This roadmap identifies actionable strategies to advance biomarker-enabled precision psychiatry and nurture cooperation, which will accelerate therapeutic innovation and improve clinical outcomes.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.